Loading stock data…
CPIX
$4.36+0.17 (+4.06%)
After Hours$4.14-0.22 (-5.05%)· Last close May 1
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cumberland Pharmaceuticals Inc. in the Healthcare sector is trading at $4.36. The stock is currently 30% below its 52-week high of $6.27, remaining 28.6% above its 200-day moving average. Technical signals show overbought RSI of 81 and bullish MACD crossover, explaining why CPIX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 81) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.36
Potential Upside
5%
Whystock Fair Value$4.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Cal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$45.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.78%
Volume
Today's trading volume
164,598
Recent News
Broadwind And 2 Promising Penny Stocks For Your Investment Radar
In the last week, the market has been flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% annually in the coming years. In this context, identifying stocks with strong financial health is crucial for investors looking to capitalize on growth opportunities. Although the term "penny stocks" might seem outdated, these shares often represent smaller or newer companies that can offer significant value and growth potential when backed by solid fundamentals.
Cumberland to sell drug portfolio to Apotex for $100m
Under the agreement, Apotex will acquire Cumberland's portfolio of branded medicines for cash.
Cumberland Pharmaceuticals jumps on $100M Apotex transaction
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares surged 80% on Thursday after the company announced a strategic deal with an affiliate of Apotex to combine their commercial operations.
Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales
CPIX's Q4 revenues jump 31%, while loss narrows year over year as sales of Vibativ, Sancuso and new product Talicia boosted its performance.
Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ...
CPIX reports significant revenue growth and global expansion, while navigating increased expenses and financial commitments.